Population Pharmacokinetics and Pharmacodynamics of Bezlotoxumab in Adults with Primary and Recurrent Clostridium difficile Infection

The fully human monoclonal antibody bezlotoxumab is indicated for preventing the recurrence of Clostridioides difficile (formerly Clostridium difficile) infection (CDI) in adults who receive antibacterial treatment for CDI and who are at high risk for a CDI recurrence. The efficacy and safety of 10-...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Antimicrob Agents Chemother
Huvudupphovsmän: Yee, Ka Lai, Kleijn, Huub Jan, Kerbusch, Thomas, Matthews, Randolph P., Dorr, Mary Beth, Garey, Kevin W., Wrishko, Rebecca E.
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Society for Microbiology 2019
Ämnen:
Clinical Therapeutics
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6355577/
https://ncbi.nlm.nih.gov/pubmed/30455246
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01971-18
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk